Multidrug resistance related genes and p53 expression in human non small cell lung cancer

Anticancer Research

Volumn 18, Issue 4 C, 1998, Pages 2973-2976

  Galimberti, Sara ^a   Marchetti, Antoni ^a   Buttitta, Fiamma ^a   Carnicelli, Vittoria ^a   Pellegrini, Silvia ^a   Bevilacqua, Generoso ^a   Petrini, Mario ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b Haematology Division   (Italy)

Author keywords

mdr1; mrp; Multidrug resistance; p53; Topoisomerase

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); MESSENGER RNA; PROTEIN P53;

ARTICLE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; P-GLYCOPROTEIN; PHENOTYPE; POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031866752     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Carulli G, Petrini M: Multidrug resistance: focus in hematology. Haematologica 75: 363-374, 1990.
2. Fojo A, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269, 1987.
3. Coon JS, Wang Y, Bines SD, Markham PN, Chong AS, Gebel MM: Multidrug resistance activity in human lymphocytes. Human Immun 32: 134-140, 1991.
4. Chaudary P, Roninson I: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human haemopoietic stem cells. Cells 66: 85-94, 1991.
5. Petrini M, Galimberti S, Sabbatini A, Bianchi F, Bernardini N, Dolfi A, Lupetti M: Expression of multidrug resistance (mdr) gene(s) in primary organs of chicken immune system during embryonic development. Experientia 51: 137-140, 1995.
6. Burt RK, Garfield S, Jhonson K, Thorgeirsson SS: Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-S-transferase and increased resistance to cytotoxic chemicals. Carcinogenesis 9: 2329-2323, 1988.
7. Chin HV, Ueda K, Pastan I, Gottesman MM: Modulation of activity of the promoter of the human MDR 1 gene by ras and p53. Science 255: 459-462, 1992.
8. Zastawny RL, Salvino R, Chen J, Benchimol S, Ling V: The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8: 1529-1535, 1993.
9. Renninson J, Baker BW, McGown AT, Murphy D, Norton JD, Fox BW, Croether D: Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopatology and clinical features. Br J Cancer 69: 609-612, 1994.
10. De Angelis P, Stokke T, Smedshamer L, Lothe RA, Lehne G, Chen Y, Clausen OP: P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 72: 307-311, 1995.
11. Marchetti A, Buttitta F, Merlo G, Diella F, Pellegrini. S, Pepe S, Macchiarini P, Chella A, Angeletti CA, Callahan R, Bistocchi M, Squartini F: p53 alterations in non small cel1 lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53: 2846-2851, 1993.
12. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Alquist KC, Stewart AJ, Kurtz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
13. Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inque H, Yamazaki H, Ueyama Y, Takagi K, Ogata T: Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72(3): 550-554, 1995.
14. Giaccone G, Van Ark-Otte J, Scagliotti G, Capranico G, Van Der Valk P, Rubio G, Dalesio O, Lopez R, Zunino F, Walboomers J: Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Bioch Bioph Acta 1264(3): 337-346, 1995.
15. World Health Organization: Histolgical typing of lung tumors. Am J Clin Pathol 77: 123-136, 1982.
16. Noonan KE, Boeck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Wilman CL, Griffith B, Von Hoff DD, Roninson IB: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87: 7160-7164, 1990.
17. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS: Analysis of multidrug resistance-associated protein (MRP) messanger RNA and malignant hemopoietic cells. Cancer Res 54: 4676-4679, 1994.
18. Beck J, Handgretinger R, Dopper R, Klingebield T, Niethammer D, Gekeler V: Expression of mdrl, mrp, topoisomerase IIa/,B and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 89: 356-363, 1995.
19. Mercer WE, Amin M, Sauve GJ, Appella E, Ullrich SJ, Romano JW: Wild type of human p53 is antiproliferative in SV-40 transformed hamster cells. Oncogene 5: 973 - 980, 1990.
20. Finlay CA, Hinds PW, Tan TH, Eliyadu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms and hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539, 1988.
21. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti CA, Bevilacqua G: mdm2 gene amplification and overexpression in non small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 4: 93-97, 1995.
22. Sabbatini ARM, Basolo F, Valentini P, Mattii L, Calvo S, Fiore L, Ciardello F, Petrini M: Induction of multidrug resistance (MDR) by transfection of MCF-10A cell line with c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer 59: 208-211, 1995.
23. Houlbrook S, Harris AL, Carmichael J, Stratford IJ: Relashionship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines. Anticancer Res 16: 1603-1610, 1996.